Knoubis Bio Inc.
San Diego, CA
- UEI
- REVESH5416V4
- CAGE
- 990N1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 4080 Rosenda Ct UNIT 211, San Diego, CA 92122, USA
- Website
- knoubisbio.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Bispecific biologic for rheumatoid arthritis therapy - abstract this proposal is focused on development of a novel… | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $312,323 | |
| Nonimmunosuppressive therapy for rheumatoid arthritis | Defense Health Agency | $2,200,000 | |
| Non-immunosuppressive rheumatoid arthritis dmard | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $548,828 |
About Knoubis Bio Inc.
Knoubis Bio Inc. is a for-profit corporate entity based in San Diego, California, focusing on innovative biomedical research in the field of rheumatoid arthritis (RA) therapy. Registered in SAM.gov since February 2022, the company specializes in developing novel biologic therapies that target inflammatory conditions, with a particular emphasis on creating non-immunosuppressive treatment approaches. The company's research appears centered on developing advanced biological therapies that can potentially improve treatment options for patients suffering from rheumatoid arthritis.
Knoubis Bio Inc. has received multiple federal grant awards from prominent health research agencies, specifically the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the Defense Health Agency. These grants, totaling approximately $3,061,151, support the company's research into developing innovative bispecific biologic therapies for rheumatoid arthritis. The federal grants, ranging from $312,323 to $2,200,000, focus on developing non-immunosuppressive disease-modifying antirheumatic drugs (DMARDs) that target fibroblast-like synoviocytes and explore novel approaches to reducing joint destruction. The research aims to address unmet medical needs by creating therapies that can enhance the efficacy of current RA treatments without causing immunosuppression, with specific research objectives including pharmacokinetic studies, demonstrating superior efficacy in mouse models, and potentially developing preclinical proof-of-concept data for future Phase II funding.
SBA capabilities narrative
Phosphatase-targeting biologics R&D
Quick answers
What is Knoubis Bio Inc.'s UEI?
Knoubis Bio Inc.'s Unique Entity ID (UEI) in SAM.gov is REVESH5416V4.
What is Knoubis Bio Inc.'s CAGE code?
Knoubis Bio Inc.'s CAGE code is 990N1.
What is Knoubis Bio Inc.'s primary NAICS code?
Knoubis Bio Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Knoubis Bio Inc. located?
Knoubis Bio Inc.'s physical address in SAM.gov is 4080 Rosenda Ct UNIT 211, San Diego, CA 92122, USA.
Is Knoubis Bio Inc. registered in SAM.gov?
Yes. Knoubis Bio Inc.'s SAM.gov registration is active through January 6, 2027.
What is Knoubis Bio Inc.'s most recent federal award?
Knoubis Bio Inc.'s most recent federal grant award is Bispecific biologic for rheumatoid arthritis therapy - abstract this proposal is focused on development of a novel… (R43AR085475), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases, on July 15, 2025.
On GovTribe
See Knoubis Bio Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors